AI Won't Fix Clinical Development Until Pharma Changes How They Use It

By Charlie Paterson Clinical development expert, PA Consulting

Clinical development teams are under pressure to make faster, better decisions — yet much of their time is still spent rebuilding context, reconciling fragmented evidence, and managing documentation rather than advancing programs. As trial complexity grows, these frictions lead to late trade‑offs, rework, and decisions that lack clear, defensible grounding.

AI offers real potential, but value emerges only when it is applied to the realities of regulated clinical development. The most effective organizations are moving beyond isolated pilots toward a role‑based operating model that aligns AI directly to how decisions are formed, documented, analyzed, and executed under GxP constraints. By treating AI as a small, connected stack — spanning evidence generation, work production, analysis, and orchestration — teams can reduce cycle times while improving quality and audit readiness.

A practical playbook shows how targeted, tightly scoped initiatives can deliver measurable impact in as little as 30 to 60 days, without replacing core systems or diluting accountability. The result is a more predictable development engine: decisions reached faster, fewer downstream surprises, and clearer narratives for regulators.

Read the full piece to see how this operating model translates into day‑to‑day gains for clinical programs.